Metabolism and Pharmacokinetics of 14C-WR 178,460.HC1 in the Dog
Abstract
The purpose of this study was to carry out a pilot investigation of the metabolism and pharmacokinetics in the beagle dog, of the compound ll4C-WR 178,460.HC1, a potential pharmacologically active metabolite of the anti-malarial drug WR 171.669.HC1. UC-WR 178,460.HC1 was administered orally, as a suspension in 1% aqueous carboxymethyl-cellulose solution, to a single dog at a dose level of 21 mg/kg. Excretion of radioactivity in faeces accounted for 72.4% dose during the first 24 hours after dosing and for 97.2% dose in seven days. A total of only 0.1% dose was excreted in urine.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 08, 1983
- Accession Number
- ADA573991
Entities
People
- C. M. Finn
- David Kirkpatrick
- David R. Hawkins